간질환 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 연평균 8.1%의 성장률로 207억 8,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 정밀의료에 대한 접근, RNA 치료제 혁신, 섬유증 치료에 대한 집중, 환자 옹호 및 지원 단체, 간염 백신 개발, 희귀질환 치료제에 대한 규제 지원 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향은 C형 간염 치료의 발전, 간섬유증에 대한 새로운 치료법의 등장, 면역 치료의 탐구, 원격의료 및 원격 모니터링, 영양 중재에 대한 집중 등입니다.
간 질환의 유병률 증가는 향후 몇 년 동안 간 질환 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 간질환은 간에 영향을 미치는 모든 질환을 포함하며, 간질환 치료제는 이러한 질환에 대처할 수 있는 다양한 치료 옵션을 제공합니다. 예를 들어, 영국 정부 부서인 Office for Health Improvement and Disparities의 보고서에 따르면, 2022년 영국의 75세 미만 간질환 사망률은 인구 10만 명당 21.4명에 달할 것으로 예상했습니다. 주목할 만한 점은 남성의 조기 사망이 6,664명인 반면 여성은 3,929명이라는 점입니다. 이처럼 간질환 유병률의 증가는 간질환 치료제 시장의 성장을 촉진하는 중요한 요인으로 작용하고 있습니다.
노인 인구의 증가는 향후 몇 년 동안 간질환 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 노인은 일반적으로 정년퇴직이나 인생의 후반부를 의미하는 일정 연령에 도달한 개인을 말합니다. 간 질환 치료제는 노인의 간 관련 건강 문제를 해결하는 데 사용되며, 간 질환을 앓고 있는 노인의 삶의 질과 전반적인 건강을 개선하고 간 건강을 효과적으로 관리하는 데 도움이 될 수 있습니다. 예를 들어, 케냐에 본사를 둔 비영리 단체인 Population Reference Bureau의 보고서에 따르면, 65세 이상의 미국인 인구는 2022년 5,800만 명에서 2050년 8,200만 명으로 47% 증가할 것으로 예상됩니다. 같은 기간 동안 이 연령대가 전체 인구에서 차지하는 비중은 17%에서 23%로 증가할 것으로 예상됩니다. 따라서 노인 인구의 증가가 간질환 치료제 시장의 성장에 기여하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 간질환 치료제 시장 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
- 최종 이용 산업 분석
- 세계의 간질환 치료제 시장 : 성장률 분석
- 세계의 간질환 치료제 시장 실적 : 규모와 성장, 2019-2024년
- 세계의 간질환 치료제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
- 세계의 간질환 치료제 전체 시장(TAM)
제6장 시장 세분화
- 세계의 간질환 치료제 시장 : 질환 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 간염
- 비알코올성 지방간
- 알코올성 간질환
- 간암
- 세계의 간질환 치료제 시장 : 치료별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 항바이러스제
- 백신
- 화학요법
- 면역억제제
- 코르티코스테로이드
- 세계의 간질환 치료제 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 병원
- 외래 수술 센터
- 기타
- 세계의 간질환 치료제 시장 : 간염 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- A형 간염
- B형 간염
- C형 간염
- D형 간염
- 세계의 간질환 치료제 시장 : 비알코올성 지방간(NAFLD) 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 비알코올성 지방간염(NASH)
- 단순 지방간
- 세계의 간질환 치료제 시장 : 알코올성 간질환 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 알코올성 간염
- 알코올성 간경변
- 세계의 간질환 치료제 시장 : 간암 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 간세포암(HCC)
- 담관암
제7장 지역별·국가별 분석
- 세계의 간질환 치료제 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 세계의 간질환 치료제 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 간질환 치료제 시장 : 경쟁 구도
- 간질환 치료제 시장 : 기업 개요
- Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- GlaxoSmithKline PLC
- Abbott Laboratories Inc.
- Pfizer Inc.
- Sanofi SA
- Johnson & Johnson Services Inc.
- Bayer AG
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Valeant Pharmaceuticals
- Watson Pharmaceuticals Inc.
- AstraZeneca PLC
- Gilead Sciences Inc.
- Endo International PLC
- Alnylam Pharmaceuticals Inc.
- Provectus Biopharmaceuticals Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 간질환 치료제 시장 2029년 : 새로운 기회를 제공하는 국가
- 간질환 치료제 시장 2029년 : 새로운 기회를 제공하는 부문
- 간질환 치료제 시장 2029년 : 성장 전략
제36장 부록
ksm
Liver disease therapeutics involve the treatment of various liver conditions, including those caused by viruses such as hepatitis A, B, and C. These therapies are crucial for improving the quality of life for individuals affected by liver diseases and for reducing the overall burden of liver disease on healthcare systems.
The primary disease classifications within liver disease therapeutics include hepatitis, non-alcoholic fatty liver disease, alcohol-induced conditions, and liver cancer. Hepatitis denotes liver inflammation caused by infectious viruses or noninfectious agents, leading to diverse health complications, some of which can be life-threatening. Treatment modalities encompass antiviral medications, vaccines, chemotherapy, immunosuppressive agents, and corticosteroids. End-users of these therapeutics span hospitals, ambulatory surgery centers, and other sectors.
The liver diseases therapeutics market research report is one of a series of new reports from The Business Research Company that provides liver diseases therapeutics market statistics, including liver diseases therapeutics industry global market size, regional shares, competitors with a liver diseases therapeutics market share, detailed liver diseases therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver diseases therapeutics industry. This liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The liver diseases therapeutics market size has grown strongly in recent years. It will grow from $14.16 billion in 2024 to $15.23 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to high prevalence of liver diseases, alcohol consumption patterns, advancements in diagnostics, obesity and metabolic syndrome, awareness and screening programs, government initiatives for hepatitis control.
The liver diseases therapeutics market size is expected to see strong growth in the next few years. It will grow to $20.78 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to precision medicine approaches, innovations in RNA therapeutics, focus on fibrosis treatments, patient advocacy and support groups, development of vaccines for hepatitis, regulatory support for orphan drugs. Major trends in the forecast period include advancements in treatment for hepatitis c, emergence of novel therapies for liver fibrosis, exploration of immunotherapies, telemedicine and remote monitoring, focus on nutritional interventions.
The increasing prevalence of liver diseases is anticipated to drive the growth of the liver disease therapeutics market in the coming years. Liver disease encompasses any condition that affects the liver, and liver disease therapeutics provide various treatment options to address these conditions. For example, a report from the Office for Health Improvement and Disparities, a UK-based government department, indicated that in 2022, the mortality rate from liver disease for individuals under 75 in England reached 21.4 per 100,000 population. Notably, there were 6,664 premature deaths among males compared to 3,929 among females. Thus, the rising incidence of liver diseases is a significant factor propelling the growth of the liver disease therapeutics market.
The expanding geriatric population is expected to drive the growth of the low-density polyethylene (LDPE) market in the coming years. The geriatric population refers to older individuals or senior citizens who have reached or surpassed a certain age, typically associated with retirement and the later stages of life. LDPE is increasingly utilized in the pharmaceutical industry to package liver disease therapeutics, which address liver-related health issues and improve the quality of life for elderly individuals. For instance, a report from the Population Reference Bureau, a Kenya-based nonprofit organization, projected that the population of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. During the same period, this age group's share of the overall population is expected to grow from 17% to 23%. Therefore, the expanding pharmaceutical industry, catering to the needs of the aging population, is contributing to the growth of the low-density polyethylene market.
Strategic partnerships represent a prominent trend in the liver disease therapeutics market. Leading companies within this sector are engaging in collaborations to fortify their positions. For instance, in January 2022, Aligos Therapeutics Inc., a US-based biopharmaceutical company, partnered with Merck & Co. to develop oligonucleotide therapies for non-alcoholic steatohepatitis. Similarly, in January 2021, Novartis collaborated with Alnylam to develop liver-targeted therapies as potential alternatives to transplantation for patients experiencing liver failure.
Prominent players in the liver disease therapeutics market prioritize innovative technologies, notably artificial intelligence (AI), to enhance patient care. AI applications in liver disease therapeutics involve sophisticated computational algorithms and machine learning techniques to analyze medical data, facilitating early detection, precise diagnosis, and personalized treatment strategies for liver diseases. For example, Predictive Health Intelligence, a UK-based healthcare information management company, unveiled hepatoSIGHT in February 2023. hepatoSIGHT, an AI-powered tool, predicts liver fibrosis in chronic liver disease patients, aiding case-finding and cohort mapping. It offers comprehensive data analysis, machine learning algorithms, real-time risk stratification, and user-friendly interfaces for efficient patient identification within seconds.
In September 2022, GENFIT, a biopharmaceutical company headquartered in France, completed the acquisition of Versantis for an undisclosed sum. This strategic acquisition integrates Versantis' specialized expertise in liver disease therapeutics with GENFIT's extensive knowledge in executing intricate development programs focused on liver diseases. This collaboration serves to reinforce and expedite research and development efforts, substantially broadening GENFIT's pipeline in this field. Versantis, based in Switzerland, specializes in therapeutic solutions for liver diseases.
Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.
North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The liver diseases therapeutics market includes revenues earned by entities by diagnosis such as imaging, laboratory tests, endoscopy, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Liver Diseases Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on liver diseases therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for liver diseases therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liver diseases therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Disease Type: Hepatitis; Non-Alcoholic Fatty Liver Disease; Alcohol-Induced; Liver Cancer
- 2) By Treatment: Antiviral; Vaccines; Chemotherapy; Immunosuppressive Agents; Corticosteroids
- 3) By End User: Hospitals; Ambulatory Surgery Centers; Other End Users
- Subsegments:
- 1) By Hepatitis: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D
- 2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH); Simple Fatty Liver
- 3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis; Alcoholic Cirrhosis
- 4) By Liver Cancer: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma
- Companies Mentioned: Astellas Pharma Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Novartis AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Liver Diseases Therapeutics Market Characteristics
3. Liver Diseases Therapeutics Market Trends And Strategies
4. Liver Diseases Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Liver Diseases Therapeutics Growth Analysis And Strategic Analysis Framework
- 5.1. Global Liver Diseases Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Liver Diseases Therapeutics Market Growth Rate Analysis
- 5.4. Global Liver Diseases Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Liver Diseases Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Liver Diseases Therapeutics Total Addressable Market (TAM)
6. Liver Diseases Therapeutics Market Segmentation
- 6.1. Global Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hepatitis
- Non-Alcoholic Fatty Liver Disease
- Alcohol-Induced
- Liver Cancer
- 6.2. Global Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antiviral
- Vaccines
- Chemotherapy
- Immunosuppressive Agents
- Corticosteroids
- 6.3. Global Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Ambulatory Surgery Centers
- Other End Users
- 6.4. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Hepatitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- 6.5. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Non-Alcoholic Fatty Liver Disease (NAFLD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Non-Alcoholic Steatohepatitis (NASH)
- Simple Fatty Liver
- 6.6. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Alcohol-Induced Liver Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Alcoholic Hepatitis
- Alcoholic Cirrhosis
- 6.7. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Liver Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hepatocellular Carcinoma (HCC)
- Cholangiocarcinoma
7. Liver Diseases Therapeutics Market Regional And Country Analysis
- 7.1. Global Liver Diseases Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Liver Diseases Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Liver Diseases Therapeutics Market
- 8.1. Asia-Pacific Liver Diseases Therapeutics Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Liver Diseases Therapeutics Market
- 9.1. China Liver Diseases Therapeutics Market Overview
- 9.2. China Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Liver Diseases Therapeutics Market
- 10.1. India Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Liver Diseases Therapeutics Market
- 11.1. Japan Liver Diseases Therapeutics Market Overview
- 11.2. Japan Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Liver Diseases Therapeutics Market
- 12.1. Australia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Liver Diseases Therapeutics Market
- 13.1. Indonesia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Liver Diseases Therapeutics Market
- 14.1. South Korea Liver Diseases Therapeutics Market Overview
- 14.2. South Korea Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Liver Diseases Therapeutics Market
- 15.1. Western Europe Liver Diseases Therapeutics Market Overview
- 15.2. Western Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Liver Diseases Therapeutics Market
- 16.1. UK Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Liver Diseases Therapeutics Market
- 17.1. Germany Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Liver Diseases Therapeutics Market
- 18.1. France Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Liver Diseases Therapeutics Market
- 19.1. Italy Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Liver Diseases Therapeutics Market
- 20.1. Spain Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Liver Diseases Therapeutics Market
- 21.1. Eastern Europe Liver Diseases Therapeutics Market Overview
- 21.2. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Liver Diseases Therapeutics Market
- 22.1. Russia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Liver Diseases Therapeutics Market
- 23.1. North America Liver Diseases Therapeutics Market Overview
- 23.2. North America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Liver Diseases Therapeutics Market
- 24.1. USA Liver Diseases Therapeutics Market Overview
- 24.2. USA Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Liver Diseases Therapeutics Market
- 25.1. Canada Liver Diseases Therapeutics Market Overview
- 25.2. Canada Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Liver Diseases Therapeutics Market
- 26.1. South America Liver Diseases Therapeutics Market Overview
- 26.2. South America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Liver Diseases Therapeutics Market
- 27.1. Brazil Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Liver Diseases Therapeutics Market
- 28.1. Middle East Liver Diseases Therapeutics Market Overview
- 28.2. Middle East Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Liver Diseases Therapeutics Market
- 29.1. Africa Liver Diseases Therapeutics Market Overview
- 29.2. Africa Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Liver Diseases Therapeutics Market Competitive Landscape And Company Profiles
- 30.1. Liver Diseases Therapeutics Market Competitive Landscape
- 30.2. Liver Diseases Therapeutics Market Company Profiles
- 30.2.1. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Liver Diseases Therapeutics Market Other Major And Innovative Companies
- 31.1. GlaxoSmithKline PLC
- 31.2. Abbott Laboratories Inc.
- 31.3. Pfizer Inc.
- 31.4. Sanofi SA
- 31.5. Johnson & Johnson Services Inc.
- 31.6. Bayer AG
- 31.7. AbbVie Inc.
- 31.8. Takeda Pharmaceutical Company Limited
- 31.9. Valeant Pharmaceuticals
- 31.10. Watson Pharmaceuticals Inc.
- 31.11. AstraZeneca PLC
- 31.12. Gilead Sciences Inc.
- 31.13. Endo International PLC
- 31.14. Alnylam Pharmaceuticals Inc.
- 31.15. Provectus Biopharmaceuticals Inc.
32. Global Liver Diseases Therapeutics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Liver Diseases Therapeutics Market
34. Recent Developments In The Liver Diseases Therapeutics Market
35. Liver Diseases Therapeutics Market High Potential Countries, Segments and Strategies
- 35.1 Liver Diseases Therapeutics Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Liver Diseases Therapeutics Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Liver Diseases Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
